Literature DB >> 7504909

High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase.

C A Boucher1, N Cammack, P Schipper, R Schuurman, P Rouse, M A Wainberg, J M Cameron.   

Abstract

Passage of human immunodeficiency virus type 1 in the presence of increasing 2'-deoxy-3'-thiacytidine (3TC) concentrations results in high-level (> 100-fold) 3TC-resistant viruses. All 3TC-resistant viruses possess a substitution at the second codon (from a methionine into an isoleucine) at position 184 within the highly conserved motif (YMDD) of human immunodeficiency virus type 1 reverse transcriptase. 3TC-resistant viruses were cross-resistant to the (-) enantiomer of the fluorinated derivative of BCH-189 but remained susceptible to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine. The susceptibilities of the 3TC-resistant viruses to the (+) enantiomers of BCH-189 and the fluorinated derivative of BCH-189 demonstrate an enantiomeric specificity for viruses selected under these conditions. Introduction of an isoleucine substitution at codon 184 into a background of two known 3'-azido-3'-deoxythymidine resistance mutations (amino acids 41 and 215) restored the susceptibility of this virus to 3'-azido-3'-deoxythymidine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7504909      PMCID: PMC192256          DOI: 10.1128/AAC.37.10.2231

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Modified protocol for DNA sequence analysis using Sequenase 2.0.

Authors:  R Schuurman; W Keulen
Journal:  Biotechniques       Date:  1991-02       Impact factor: 1.993

2.  Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds.

Authors:  R Pauwels; J Balzarini; M Baba; R Snoeck; D Schols; P Herdewijn; J Desmyter; E De Clercq
Journal:  J Virol Methods       Date:  1988-08       Impact factor: 2.014

3.  Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity.

Authors:  B A Larder; S D Kemp; D J Purifoy
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

4.  Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity.

Authors:  B Chesebro; K Wehrly
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

5.  In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine.

Authors:  R Yarchoan; H Mitsuya; R V Thomas; J M Pluda; N R Hartman; C F Perno; K S Marczyk; J P Allain; D G Johns; S Broder
Journal:  Science       Date:  1989-07-28       Impact factor: 47.728

6.  Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture.

Authors:  B A Larder; K E Coates; S D Kemp
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

7.  Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay.

Authors:  B A Larder; B Chesebro; D D Richman
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

8.  Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine.

Authors:  P Kellam; C A Boucher; B A Larder
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

9.  Trans-acting transcriptional activation of the long terminal repeat of human T lymphotropic viruses in infected cells.

Authors:  J G Sodroski; C A Rosen; W A Haseltine
Journal:  Science       Date:  1984-07-27       Impact factor: 47.728

10.  Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).

Authors:  R Yarchoan; C F Perno; R V Thomas; R W Klecker; J P Allain; R J Wills; N McAtee; M A Fischl; R Dubinsky; M C McNeely
Journal:  Lancet       Date:  1988-01-16       Impact factor: 79.321

View more
  95 in total

1.  Antiviral activity of 2'-deoxy-3'-oxa-4'-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice.

Authors:  C A Stoddart; M E Moreno; V D Linquist-Stepps; C Bare; M R Bogan; A Gobbi; R W Buckheit; J Bedard; R F Rando; J M McCune
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

2.  A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidine.

Authors:  R A Smith; G J Klarmann; K M Stray; U K von Schwedler; R F Schinazi; B D Preston; T W North
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

3.  Prevalence and conditions of selection of E44D/A and V118I human immunodeficiency virus type 1 reverse transcriptase mutations in clinical practice.

Authors:  C Delaugerre; M Mouroux; A Yvon-Groussin; A Simon; F Angleraud; J M Huraux; H Agut; C Katlama; V Calvez
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

4.  Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence.

Authors:  M C Strain; H F Günthard; D V Havlir; C C Ignacio; D M Smith; A J Leigh-Brown; T R Macaranas; R Y Lam; O A Daly; M Fischer; M Opravil; H Levine; L Bacheler; C A Spina; D D Richman; J K Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-08       Impact factor: 11.205

Review 5.  Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Karidia Diallo; Matthias Götte; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

6.  A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Authors:  Robert W Shafer; Kathryn Dupnik; Mark A Winters; Susan H Eshleman
Journal:  HIV Seq Compend       Date:  2001

7.  Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.

Authors:  Thomas P Young; Neil T Parkin; Eric Stawiski; Tami Pilot-Matias; Roger Trinh; Dale J Kempf; Michael Norton
Journal:  Antimicrob Agents Chemother       Date:  2010-08-30       Impact factor: 5.191

8.  In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.

Authors:  Masanori Kobayashi; Tomokazu Yoshinaga; Takahiro Seki; Chiaki Wakasa-Morimoto; Kevin W Brown; Robert Ferris; Scott A Foster; Richard J Hazen; Shigeru Miki; Akemi Suyama-Kagitani; Shinobu Kawauchi-Miki; Teruhiko Taishi; Takashi Kawasuji; Brian A Johns; Mark R Underwood; Edward P Garvey; Akihiko Sato; Tamio Fujiwara
Journal:  Antimicrob Agents Chemother       Date:  2010-11-29       Impact factor: 5.191

9.  Development of an in vivo assay to identify structural determinants in murine leukemia virus reverse transcriptase important for fidelity.

Authors:  E K Halvas; E S Svarovskaia; V K Pathak
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 10.  HIV resistance to raltegravir.

Authors:  Francois Clavel
Journal:  Eur J Med Res       Date:  2009-11-24       Impact factor: 2.175

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.